Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: Synergy Pharmaceuticals (SGYP) Ready To Roll

(EMAILWIRE.COM, May 22, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, reported today that Synergy Pharmaceuticals (SGYP) may be in a position to realize significant share price gains over the coming months.



Synergy Pharmaceuticals (SGYP) ran to over seven dollars last month on increasing volume as the company's billion dollar potential took shape and numerous analysts jumped on board with encouraging write-ups and bold price predictions.



Synergy also received a boost when its chief competitor, Ironwood Pharmaceuticals (IRWD) received a setback at the FDA that allows SGYP an extra three months to play catch up in the race to commercialization for each company's respective product candidate, both of which target the same indication. Synergy's product Plecanatide, however, has a much more favorable side effect profile, making the Ironwood setback that much more of a key factor when discussing future market potential.



Both products, Synergy's Plecanatide and Ironwood's Linaclotide, are being developed to treat chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Linaclotide is already before the FDA for review, although the review was delayed by three months, as mentioned before, while Phase II/III Plecanatide results are due out later this year.



The head start to market may provide Ironwood with a distinct advantage, but the advantage might not last too long when Plecanatide shows up on the scene.



During the Linaclotide trials, the drug was successful in alleviating symptoms relating to IBS-C and CIC when compared to a placebo, but the kicker is that patients experienced side effects that included cases of extreme diarrhea, essentially reversing the symptom being treated. Some cases of diarrhea were so bad that 6% of the patients decided to abandon the trial altogether.



On the open market - with a competing product out there for which there have been no such cases noted - that means those patients would likely switch to the alternative, in this case Plecanatide, that is not associated with carrying around a roll of Charmin' Soft at all times.



For full report visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-sgyp-may-be-ready-to-roll



For full report and opinion visit: http://vfcsstockhouse.com/blog/article/-the-facebook-fb-ipo-don-t-believe-the-hype



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com:



VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com







VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

US eating habits improve a bit _ except among poor
1 Sep 2014 at 1:29pm

Americans' eating habits have improved ? except among the poor, evidence of a widening wealth gap when it comes to diet. Yet even among wealthier adults, food choices remain far from ideal, a 12-year study ...


Study: Action-packed TV might make you snack more
1 Sep 2014 at 1:08pm
CHICAGO (AP) ? Could action-packed TV fare make you fat? That's the implication of a new study that found people snacked more watching fast-paced television than viewing a more leisurely paced talk show.


Novartis Japan admits concealing drug side effects
1 Sep 2014 at 12:56pm

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities. The revelations, which marked the latest in a string of scandals at the company's Japanese subsidiary, come after local authorities slapped the firm on the wrist, saying it had to clean up its operations. On Friday, Novartis issued a statement saying it had failed to report to regulators at least 2,579 cases where patients had suffered serious potential side effects from its drugs. Japanese media said the number of cases involved could rise as Novartis probes 6,000 other cases.



Parents of ill UK boy fight extradition from Spain
1 Sep 2014 at 12:36pm

LONDON (AP) ? The parents say they want to give their 5 year-old-boy with a brain tumor the best chance to live with a revolutionary new treatment they learned about on the Internet. Their British hospital says the boy has a 70 percent to 80 percent chance of survival with the treatment it offers, and it's the parents who are putting the child at risk.



Senegal monitors contacts of 1st Ebola patient
1 Sep 2014 at 10:55am

DAKAR, Senegal (AP) ? Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.



Human Trial for Ebola Vaccine to Begin This Week
1 Sep 2014 at 10:13am

GlaxoSmithKline Makes Vaccine Stockpiles



Parents of seriously ill British boy resist extradition from Spain
1 Sep 2014 at 10:06am

The British parents who sparked a major manhunt by taking their seriously ill son out of hospital last week have asked a Spanish court not to extradite them to the United Kingdom, a judicial source said on Monday. Brett and Naghemeh King are wanted in the United Kingdom after removing their son Ashya, 5, who is suffering from a brain tumour, from Southampton General Hospital in southern England on Thursday, raising fears his life could be at risk. "They have said they don't want to be handed over to the British authorities," the source told Reuters. A panel of three judges will now have to decide whether to extradite the parents to the United Kingdom from Madrid, a process which could take weeks, said the source.



Pricing is key for new heart drugs challenging cheap generics
1 Sep 2014 at 9:57am

While new treatments on show in Barcelona are certainly moving cardiovascular medicine forward after a series of setbacks in recent years, cardiologists say that cost will be key in determining how widely they are used. ?We are entering a new era of treatment and, of course, it will cost a lot of money, which is a problem,? said Michel Bertrand, emeritus professor at the University of Lille and a past president of the European Society of Cardiology (ESC). Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies. Novartis's new heart failure drug LCZ696, for example, was tested in a pivotal trial against enalapril, a generic drug in the so-called ACE inhibitor class, a month's supply of which can be bought at Wal-Mart stores for only $4.



Poor response to Ebola causing needless deaths: World Bank head
1 Sep 2014 at 9:47am

By Daniel Flynn and Tim Cocks DAKAR/LAGOS (Reuters) - The world's "disastrously inadequate response" to West Africa's Ebola outbreak means many people are dying who could easily be saved, the head of the World Bank said on Monday, as Nigeria confirmed another case of the highly contagious virus. In a newspaper editorial, World Bank President Jim Yong Kim said Western healthcare facilities would easily be able to contain the disease, and he urged wealthy nations to share knowledge and resources to help African countries tackle it. ...



Drama of mother starving baby grips Venice fest
1 Sep 2014 at 8:13am

By Michael Roddy VENICE (Reuters) - A film portraying New York City mother who starves her baby because she thinks he is saint-like and food contains impurities has caused a stir at the Venice Film Festival for its switch from light romance to painful psychosis. "Hungry Hearts", by Italian director Saverio Costanzo, is one of two Italian films shown so far this week that are among 20 films competing for the top Golden Lion award at the world's oldest film festival. It stars Adam Driver, who will be in the next "Star Wars" series, and Italian actress Alba Rohrwacher as his wife. The film, which was shot for a budget of under 1 million euros ($1.3 million), starts off in rom-com style when Driver's character Jude, who works as an engineer, and Rohrwacher's Mina, who works at the Italian embassy, are both accidentally locked in the toilet of a Chinese restaurant.



Ebola health workers should get danger money, expert says
1 Sep 2014 at 8:08am

By Misha Hussain DAKAR (Thomson Reuters Foundation) - Doctors and nurses fighting the world's biggest outbreak of the Ebola virus in West Africa should get incentives including better pay, insurance and access to the new Ebola drug ZMapp, an international health expert said. The hemorrhagic fever, spread through the blood, sweat and vomit of the sick, has killed more than 1,550 people since March, including more than 120 health workers. Johan von Schreeb, who has traveled to the region to advise officials on how to manage the deadly epidemic, said if health workers were not protected and remunerated for their dangerous work, they could not be expected to report for duty. "Modern mobile phone technology can be used to track who is coming to work as well as transferring money directly so they can be paid on a performance-based system on top of their normal salaries," he told Thomson Reuters Foundation from Sierra Leone, where he is providing technical support for the outbreak.


Exercise to reap the heart-health benefits of wine, study says
1 Sep 2014 at 8:08am

At the European Society of Cardiology Congress, researchers from the Czech Republic presented a first of its kind study in which they concluded that wine has its greatest cardiovascular benefits for those who exercise. "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis in people at mild to moderate risk of CVD," says Professor Milos Taborsky, Director of the Internal Cardiology Clinic of the University Hospital and Palacky University in Olomouc. "We found that moderate wine drinking was only protective in people who exercised. Red and white wine produced the same results."



Pistachios may help reduce diabetes risk: study
1 Sep 2014 at 7:29am

By Kathryn Doyle NEW YORK (Reuters Health) - For people who may be headed for type 2 diabetes, regularly eating pistachios might help turn the tide, according to a new trial from Spain. People with so-called prediabetes have blood sugar levels higher than normal but not yet in the diabetes range. If they do nothing, 15 to 30 percent will develop diabetes within five years, according to the U.S. In the new Spanish study, people with prediabetes who ate about two ounces of pistachios daily showed significant drops in blood sugar and insulin levels and improvements in insulin and glucose processing.


Nigeria records another Ebola case in oil city, 16 cases in total
1 Sep 2014 at 6:45am
Nigeria has a third confirmed case of Ebola disease in the oil hub of Port Harcourt, bringing the country's total confirmed infections to 16, with around 200 people under surveillance, the health minister said on Monday. A doctor in Port Harcourt died last week after treating a contact of the Liberian-American man who was the first recorded case of the virus in Africa's most populous country. Patrick Sawyer, the first case, came in from Liberia, then collapsed at Lagos airport on July 20. The shift to Port Harcourt shows how easily containment efforts can be undermined.

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden
1 Sep 2014 at 6:14am
India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product. Cipla's drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday. In December, Denmark became the first European country to approve for sale a generic version of GlaxoSmithKline's $8 billion-a-year Advair, and analysts have been expecting more such approvals.

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC